Corflow
Vision
To be the leader in diagnostic and therapeutic solutions for restoring healthy microvascular blood flow anywhere in the human body where a critical need exists.
Menu
To be the leader in diagnostic and therapeutic solutions for restoring healthy microvascular blood flow anywhere in the human body where a critical need exists.
To be the leader in diagnostic and therapeutic solutions for restoring healthy microvascular blood flow anywhere in the human body where a critical need exists.
CEO
18 years at Medtronic, 14 years in the fields of vascular and interventional cardiology.
Head of Operations and Supplier Engineering
12+ yrs experience in medical device development in the field of cardiology.
Head of Quality
25+ yrs of experience in regulatory affairs, quality assurance and post market surveillance.
Head of Science and Technology
PhD in Biomedical Engineering 8+ yrs experience in cardiovascular research and expert in fluid dynamics.
Head of Product Development
8+ yrs in medical device R&D, co-founder of MedTech startup, PhD in Biomedical Engineering.
Head of Medical Affairs and Market Development
25 + years experience in pharmaceuticals and devices in cardiology and vascular.
Head of Clinical Affairs
PhD in Immunology 19 yrs of experience in cardiology Clinical affairs and life sciences.
Chairman
CEO
Broadview Ventures
Merieux Partners
Laerdal Million Lives Fund
Panakes Partners
415 Capital
Panakes Partners
Broadview Ventures
KOFA Healthcare
M&L Investments
Laerdal Million Lives Fund
Physician Co-Founder
Wellington
Merieux Partners
Arcu ac tortor dignissim convallis aenean et tortor at risus. Nisl nisi scelerisque eu ultrices vitae. Aenean euismod elementum nisi quis eleifend quam adipiscing vitae. Augue ut lectus arcu bibendum at. Mauris augue neque gravida in fermentum et sollicitudin. Condimentum lacinia quis vel eros donec ac. Tellus at urna condimentum mattis pellentesque id nibh tortor id.
Consequat mauris nunc congue nisi. Ac feugiat sed lectus vestibulum mattis ullamcorper velit sed. Sit amet nisl purus in. Dui vivamus arcu felis bibendum ut tristique et. Aliquet porttitor lacus luctus accumsan. Quam quisque id diam vel quam elementum pulvinar. Tempor orci dapibus ultrices in iaculis nunc sed augue. Duis tristique sollicitudin nibh sit amet commodo nulla facilisi nullam.
Eu ultrices vitae auctor eu augue ut. Ac tortor dignissim convallis aenean et tortor at risus viverra. Ac turpis egestas maecenas pharetra. Eu facilisis sed odio morbi quis commodo odio aenean sed. Consequat mauris nunc congue nisi vitae. Eu feugiat pretium nibh ipsum consequat nisl vel pretium. Maecenas accumsan lacus vel facilisis volutpat est velit. Velit ut tortor pretium viverra suspendisse potenti nullam ac tortor. Phasellus egestas tellus rutrum tellus pellentesque eu tincidunt.
Ipsum dolor sit amet consectetur adipiscing elit pellentesque habitant morbi. Massa tincidunt dui ut ornare. Elit sed vulputate mi sit amet mauris. Euismod nisi porta lorem mollis aliquam ut porttitor leo a. Id velit ut tortor pretium viverra suspendisse potenti nullam. Volutpat lacus laoreet non curabitur gravida arcu ac. Orci sagittis eu volutpat odio facilisis mauris.
The CoFI-System is not approved in the United States of America. It is an investigational device limited by federal law to investigational use and is not available for commercial distribution.
VAT:CHE 320.873.257 MWST
© 2023 Corflow. All Rights Reserved.
Rick is the Founder and Chief Executive Officer of Cyrano Therapeutics, a private company that has developed a treatment to restore the sense of smell and flavor in those who have lost it. He is also a member of the Executive Committee and the Board of Directors for MDIC, the Medical Device Innovation Consortium, Chairman of Aventamed and Vice Chairman of The Mullings Group. Further board positions include SoundBite Medical Solutions and Cardiac Implants. Rick has more than 35 years of management experience in the medical device industry with more than 30 years in the cardiovascular device space. Rick has previously led the company foundation for four medical device companies: Mitralign (acquired by Edwards), CircuLite (acquired by HeartWare), FlowMedica (acquired by Angiodynamics) and X-Cell and guided the recapitalization and redirection of two other successful medical device companies: Impella (acquired by Abiomed) and Pathway (acquired by Bayer). Mr. Geoffrion has served as the Chairman of Impella CardioSystems AG, CircuLite and FlowMedica, Inc.. He received a BSME and an MBA from the University of Connecticut.
Gunnar has over 40 year’s experience in medical device distribution, start-ups and financing. He started as a sales manager in Medico (Oslo, Norway) and has founded successful distribution companies in Europe (Medi-Stim AS (1984), CardioMed GmbH (1994) and MicroMed (1994)). Gunnar is an active early stage investor in several breakthrough interventional cardiology companies of which many have had a successful exit: AVE, Vascular Science, Atritech, Embolic Protection, Rubicon, Sapheon, Loma Vista, CoreValve and CardiAQ.
Erik is the chairman and founder of NeoMed Management and was previously the chairman and controlling shareholder of NeoMed AS, providing investment advisory services, specializing in small and medium sized companies in the pharmaceutical, medical device and diagnostic industries. Erik has served as a board member of a. o. Clavis Pharma AS (which went public on the Oslo Stock Exchange), GenoVision AS (sold to Qiagen), Thommen Medical AG (investment sold in a private secondary sale) and Vessix Vascular Inc. (sold to Boston Scientific Corporation), and currently serves on the Board of Directors of Axonics Modulation Technologies Inc. (USA), JenaValve Technology Inc. (USA, Germany), Sequana Medical AG (Switzerland) and Sonendo Inc. (USA). Erik is a founder and former chairman of the Norwegian Venture Capital Association. He holds a Dr. Scient. degree in organic chemistry from the University of Oslo and a Master of Science degree in Management from the Graduate School of Business, Stanford University, USA.
Cardiologist & VP Medical Affairs Medtronic Co-Founder of CorFlow Therapeutics AG, Chief Medical Officer and VP of Medical Affairs, Medtronic Coronary, RDN & Structural Heart, Santa Rosa, CA, USA, Honorary Professor of Interventional Cardiology, Queen Mary, University of London, United Kingdom Martin is a world-renown and NHS pioneer in interventional cardiology and has founded numerous cardiology medical device companies raising more than £300M for these early stage companies. He joined Medtronic in 2010 and is now responsible for a wide product spectrum from coronary&vascular disease to resistant hypertension and minimally invasive heart valves.
